TABLE 3

Pharmacological Profile of P2X3R

EC50/IC50 values are micromolar unless otherwise specified.

CompoundMethodEC50/IC50References
Full agonists
    ATPCurrent1Lewis et al., 1995; Chen et al., 1995
    αβ-meATPCurrent1–2Lewis et al., 1995; Chen et al., 1995
    2-meSATPCurrent0.3Lewis et al., 1995; Chen et al., 1995; Garcia-Guzman et al., 1997
    Ap6ACurrent1.5Wildman et al., 1999a
    Ap5ACurrent1Wildman et al., 1999a
    Ap4ACurrent1Wildman et al., 1999a
Partial agonists
    ATPγSCurrent10Liu et al., 2001
    BzATPCalciumN.D.Jarvis et al., 2001; He et al., 2002
    βγ-meATPCurrent>300Chen et al., 1995
Antagonists
    SuraminCurrent3Lewis et al., 1995
    PPADSCurrent1.5Lewis et al., 1995
    TNP-ATPCurrent1 nMVirginio et al., 1998b
    A-317491Current/Ca2+20 nMJarvis et al., 2002
    NF023Current8.5Soto et al., 1999
    NF279Current2Rettinger et al., 2000
    NF449Current3Braun et al., 2001
    RO-85Calcium30 nMBrotherton-Pleiss et al., 2010
    Ip4ICurrent1King et al., 1999
    MRS2159Current150 nMKim et al., 2001
    MRS2257Current30 nMKim et al., 2001
    AF-353Current/Ca2+10 nMGever et al., 2010
    RO-4Calcium13 nMCarter et al., 2009
    RO-51Calcium10 nMJahangir et al., 2009
Modulators
    Protons (−)CurrentpKa 6.0Stoop et al., 1997; Gerevich et al., 2007
    Calcium (−)Current90 mMVirginio et al., 1998a
    Zinc (+) aCurrent10Wildman et al., 1999b
    Cadmium (−)Current100Nakazawa and Ohno, 1997
    Ethanol (+)Current25 mMDavies et al., 2005a
    Cibracon Blue (+)Current/Ca2+1.5Alexander et al., 1999
    Toluene (−)Current3 mMWoodward et al., 2004
    TetramethylpyrazineCurrent1 mMGao et al., 2008
    Cdk-5 (−)CurrentNair et al., 2010
    Csk (−)CurrentD'Arco et al., 2009
  • N.D., not determined; (+), positive modulator; (−), negative modulator; Cdk-5, cyclin-dependent kinase 5; Src, C-terminal Src kinase.

  • a Biphasic effects, suggesting the existence of more than one allosteric site.